Chondrofix Osteochondral Allograft Prospective Study

A Post Market Study to Evaluate the Chondrofix® Osteochondral Allograft Utilized for Treatment of Subjects With Cartilage Lesions in the Knee

The overall study objective is to evaluate Chondrofix Osteochondral Allograft ("Chondrofix") for the repair of osteochondral lesions in the knee. This includes, but is not limited to primary cartilage lesion repair and revision of failed prior cartilage repair treatments. The study hypothesis is that Chondrofix Allograft will provide pain relief and functional improvement as demonstrated by a comparative analysis of baseline clinical evaluations at 24 months of follow-up.

Study Overview

• Status: Terminated
• Conditions: Defect of Articular Cartilage; Articular Cartilage Disorder; Degeneration; Articular Cartilage; Chronic Cartilage Injury; Acute Cartilage Injury
• Intervention / Treatment: Procedure: Chondrofix Osteochondral Allograft

Detailed Description

Knee cartilage injuries are a major cause of pain and functional impairment in young to middle age adults and can lead to progressive joint degeneration. In response to challenges with current cartilage repair options, Chondrofix Allograft was developed as an off-the-shelf treatment option adding to the variety of cartilage reparation offerings.

This study is a multicenter, prospective, post-market clinical outcomes study designed to assess the clinical outcomes of Chondrofix Allograft used in the treatment of both primary and revision cartilage repair cases. Study design includes up to 6 qualified investigational sites with 50 subjects enrolled across all centers during an 18 month enrollment period. Study subjects will be followed postoperatively for 5 years. The Investigators who are responsible for the conduct of this study in compliance with this protocol will be orthopedic surgeons who are skilled in the techniques of articular cartilage repair.

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Connecticut
    • Cos Cob, Connecticut, United States, 06807
      • Plancher Orthopaedics and Sports Medicine
    • New Haven, Connecticut, United States, 06511
      • The Orthopaedic Group, LLC
  • Indiana
    • Greenwood, Indiana, United States, 46143
      • Orthopaedic Research Foundation, Inc.
  • Massachusetts
    • Chestnut Hill, Massachusetts, United States, 02467
      • Cartilage Repair Center, Brigham and Women's Hospital
  • Ohio
    • Columbus, Ohio, United States, 43215
      • Specialized Orthopaedics and Sports Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Generally, the following inclusion criteria must be met, however, this is not a complete list.

• Male and non-pregnant female subjects between 18 and 70 years; subject must be skeletally mature
• If female, subjects are not pregnant at time of surgery and do not plan on becoming pregnant during the first 24 months of the study
• Up to two (2) cartilage lesion(s), each measuring less than 8 cm2, of the femoral condyle or trochlear groove of the knee
• Localized knee pain unresponsive to conservative treatment (e.g., medication, bracing, physical therapy) and/or previous surgical intervention

Exclusion Criteria:

Generally, if a potential participant meets any of the following criteria, they will not be eligible for this study. Additionally, more criteria will be evaluated to confirm eligibility as this list is not a complete list of criteria.

• Concurrent participation in another clinical trial
• Cartilage lesion location is such that the implanted graft(s) will not be adequately shouldered
• Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface)
• Is receiving pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee condition
• Subject had any other cartilage repair procedure other than debridement performed in conjunction with or 6 months prior to implantation of a Chondrofix Osteochondral Allograft
• Prior or concurrent total meniscectomy of the index knee
• Uncorrected mal-alignment of the index knee
• Have smoked or used nicotine products within the past 6 months
• Body Mass Index > 35 (BMI=kg/m2)
• Has any contraindications for MRI
• Requires any of the following concomitant procedures performed in conjunction with or has had performed within 6 months prior to implantation of a Chondrofix Allograft: distal realignment, high tibial osteotomy, ligament reconstruction, and/or patellar realignment procedure
• Septic or reactive arthritis or systemic disease (e.g., rheumatoid arthritis, gout or prior history of gout or pseudo gout)
• Sickle cell disease, hemochromatosis, or autoimmune disease
• Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes
• HIV or other immune-deficient state including subject on immunosuppressant therapies
• Deficiency limiting ability to perform an objective functional assessment of the operative knee or an inability to adhere to a post-operative rehabilitation protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Chondrofix; Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove	Procedure: Chondrofix Osteochondral Allograft; Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone; Other Names: Chondrofix

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
KOOS Subscale	The overall mean change from baseline to 24 months in the KOOS Pain and KOOS Function in Daily Living (ADL) subscale scores.	24 Months

Secondary Outcome Measures

Outcome Measure	Time Frame
X-ray & MRI Evaluation	Baseline and 1.5, 3, 6, 12, 24, & 60 months
IKDC Knee Examination	Baseline & 1.5, 3, 6, 12, 24, & 60 months
Subject Reported Questionnaires	Baseline and 1.5, 3, 6, 12, 24, 36, 48, and 60 months

Collaborators and Investigators

• Sponsor: Zimmer Orthobiologics, Inc.
• Investigators: Study Chair: Nikesha N Harrington, Zimmer Orthobiologics, Inc.

Study record dates

Study Major Dates

• Study Start: April 1, 2011
• Primary Completion (Actual): March 1, 2014
• Study Completion (Actual): March 1, 2014

Study Registration Dates

• First Submitted: August 2, 2011
• First Submitted That Met QC Criteria: August 2, 2011
• First Posted (Estimate): August 4, 2011

Study Record Updates

• Last Update Posted (Estimate): August 11, 2014
• Last Update Submitted That Met QC Criteria: August 7, 2014
• Last Verified: August 1, 2014

More Information

Terms related to this study

• Keywords: OCD; Knee; Lesions; Femur; Articular cartilage; Defects; Osteochondral graft; Cartilage treatments; Osteochondritis Dissecans
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Connective Tissue Diseases; Wounds and Injuries; Cartilage Diseases
• Other Study ID Numbers: CSU2010-14B